Myriad Genetics, Inc. (NASDAQ:MYGN) headquartered in Salt Lake City, will host a conference call for the investment community to discuss the 1Q21 earnings result on 9th November 2020 at 5:00 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit myriad.com
Earnings Expectation
Myriad Genetics, Inc. is reporting first quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.3 per share from $ 135.21 million in revenue. For the full year, analysts predict revenues of $ 654.84 million, while looking forward to loss of $ 0.18 per share.
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis.
